Immuno-Oncology Diagnostics, The Race for Biomarkers, Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024
|発行||Howe Sound Research||商品コード||804234|
|出版日||ページ情報||英文 277 Pages
|癌免疫診断市場の予測・分析：バイオマーカーを巡る争い Immuno-Oncology Diagnostics, The Race for Biomarkers, Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024|
|出版日: 2019年10月02日||ページ情報: 英文 277 Pages||
Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.
The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry. Mr. Powell's education includes:
B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research Seminar - Burke Institute
Finance for Senior Executives - Harvard Business School